Angelini Pharma secures US foothold with $4.1bn Catalyst
Italian pharmaceutical group Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals in an all-cash transaction valued at $4.1bn. The acquisition marks a pivotal expansion for the privately held European drugmaker, establishing its first direct commercial footprint in the United States while bolstering its central nervous system and rare disease portfolio. The transaction is expected to close in the third quarter…